$5.76 Billion in Sales Expected for AstraZeneca plc (AZN) This Quarter
Wall Street analysts predict that AstraZeneca plc (NYSE:AZN) will announce sales of $5.76 billion for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for AstraZeneca’s earnings. The lowest sales estimate is $5.37 billion and the highest is $6.12 billion. AstraZeneca reported sales of $5.59 billion during the same quarter last year, which would suggest a positive year over year growth rate of 3%. The business is expected to announce its next earnings results before the market opens on Friday, February 2nd.
On average, analysts expect that AstraZeneca will report full-year sales of $5.76 billion for the current fiscal year, with estimates ranging from $20.03 billion to $22.48 billion. For the next fiscal year, analysts forecast that the company will post sales of $22.07 billion per share, with estimates ranging from $20.47 billion to $23.93 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover AstraZeneca.
AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.55. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The business had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the previous year, the firm earned $1.32 EPS. The company’s revenue was up 9.4% compared to the same quarter last year.
Shares of AstraZeneca (AZN) opened at $35.65 on Friday. AstraZeneca has a 12-month low of $26.51 and a 12-month high of $35.92. The company has a market cap of $89,648.45, a price-to-earnings ratio of 8.45, a P/E/G ratio of 3.39 and a beta of 0.72. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72.
A number of institutional investors have recently made changes to their positions in AZN. WFG Advisors LP raised its position in AstraZeneca by 36.0% during the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after buying an additional 984 shares during the last quarter. Valeo Financial Advisors LLC purchased a new position in AstraZeneca during the 3rd quarter worth $133,000. Quadrant Capital Group LLC raised its position in AstraZeneca by 18.4% during the 2nd quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock worth $147,000 after buying an additional 846 shares during the last quarter. Wealthcare Advisory Partners LLC purchased a new position in AstraZeneca during the 3rd quarter worth $184,000. Finally, FTB Advisors Inc. raised its position in AstraZeneca by 3.2% during the 2nd quarter. FTB Advisors Inc. now owns 6,471 shares of the company’s stock worth $197,000 after buying an additional 200 shares during the last quarter. Institutional investors own 14.75% of the company’s stock.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.